Gingerol-derivatives: Emerging new therapy against human drug-resistant MCF-7

Ahmed Salah Ibrahim, Mohamed A.M. Sobh, Hossam Mohammed Eid, Amgad Salem, Hossam Hamza Elbelasi, Mai H. El-Naggar, Fatma M. Abdelbar, Hussein Sheashaa, Mohamed A. Sobh, Farid A. Badria

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cancer chemotherapies have been improved dramatically over the last two decades. In the case of human breast cancer, the combination chemotherapeutic protocol, cyclophosphamide (CPA), doxorubicin (DOX), and 5-fluorouracil (5-FU) (CDF), is often used. Nevertheless, the clinical usefulness of CDF is limited by its remarkably low therapeutic window and frequent eruption of resistance. These limitations prompted our search for a more effective and safe drug candidate that may raise the therapeutic benefits for breast cancer patients. Gingerols’ wide therapeutic indices as well as their high efficacy in the suppression of carcinogenesis are well established. However, no thorough study to date has profiled their antibreast cancer activities in depth. Therefore, the aims of the present study are to evaluate the antibreast cancer activities of gingerols in comparison to CDF and to gain insight into the structure activity relationships (SARs) responsible for the observed effect using a breast cancer cell model, MCF-7. Our data revealed that 6-gingerol showed the highest anticancer potency that is superior to that of CDF with IC50=30.4 μM. Guided by these results, semisynthetic modifications of 6-gingerol have been carried out to characterize 6-gingerol’s SARs. The obtained results showed that the acquisition of free hydroxyl group in the aliphatic side chain of 6-gingerol is essential for the antibreast cancer activity. Likewise, the length of aliphatic side chain in 6-gingerol is optimum for its anticancer activity because any decrease in the side chain length resulted in a dramatic loss of anticancer activity. Additionally, allylation of phenolic group has shown antibreast cancer activity superior to that of 6-gingerol per se. Conversely, methylation or isoprenylation of phenolic group has led to a potential decrease in the anticancer activity, whereas loss of aromaticity resulted in a complete loss of 6-gingerol’s cytotoxic activity. Collectively, the present results would simplify drug design to allow safer and more effective antibreast cancer pharmaceuticals to be designed.

Original languageEnglish (US)
Pages (from-to)9941-9948
Number of pages8
JournalTumor Biology
Volume35
Issue number10
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Pharmaceutical Preparations
Neoplasms
Therapeutics
Structure-Activity Relationship
Breast Neoplasms
Prenylation
gingerol
Drug Design
MCF-7 Cells
Fluorouracil
Hydroxyl Radical
Doxorubicin
Cyclophosphamide
Methylation
Inhibitory Concentration 50
Carcinogenesis
Drug Therapy

Keywords

  • 5-fluorouracil
  • Allyl 6-gingerol
  • Anticancer drug
  • Breast cancer
  • CF-7
  • Cyclophosphamide
  • Doxorubicin
  • Gingerol

ASJC Scopus subject areas

  • Cancer Research

Cite this

Ibrahim, A. S., Sobh, M. A. M., Eid, H. M., Salem, A., Elbelasi, H. H., El-Naggar, M. H., ... Badria, F. A. (2014). Gingerol-derivatives: Emerging new therapy against human drug-resistant MCF-7. Tumor Biology, 35(10), 9941-9948. https://doi.org/10.1007/s13277-014-2248-7

Gingerol-derivatives : Emerging new therapy against human drug-resistant MCF-7. / Ibrahim, Ahmed Salah; Sobh, Mohamed A.M.; Eid, Hossam Mohammed; Salem, Amgad; Elbelasi, Hossam Hamza; El-Naggar, Mai H.; Abdelbar, Fatma M.; Sheashaa, Hussein; Sobh, Mohamed A.; Badria, Farid A.

In: Tumor Biology, Vol. 35, No. 10, 01.01.2014, p. 9941-9948.

Research output: Contribution to journalArticle

Ibrahim, AS, Sobh, MAM, Eid, HM, Salem, A, Elbelasi, HH, El-Naggar, MH, Abdelbar, FM, Sheashaa, H, Sobh, MA & Badria, FA 2014, 'Gingerol-derivatives: Emerging new therapy against human drug-resistant MCF-7', Tumor Biology, vol. 35, no. 10, pp. 9941-9948. https://doi.org/10.1007/s13277-014-2248-7
Ibrahim AS, Sobh MAM, Eid HM, Salem A, Elbelasi HH, El-Naggar MH et al. Gingerol-derivatives: Emerging new therapy against human drug-resistant MCF-7. Tumor Biology. 2014 Jan 1;35(10):9941-9948. https://doi.org/10.1007/s13277-014-2248-7
Ibrahim, Ahmed Salah ; Sobh, Mohamed A.M. ; Eid, Hossam Mohammed ; Salem, Amgad ; Elbelasi, Hossam Hamza ; El-Naggar, Mai H. ; Abdelbar, Fatma M. ; Sheashaa, Hussein ; Sobh, Mohamed A. ; Badria, Farid A. / Gingerol-derivatives : Emerging new therapy against human drug-resistant MCF-7. In: Tumor Biology. 2014 ; Vol. 35, No. 10. pp. 9941-9948.
@article{8cb8aa6b9cf44b3c8e0cccd7db722de1,
title = "Gingerol-derivatives: Emerging new therapy against human drug-resistant MCF-7",
abstract = "Cancer chemotherapies have been improved dramatically over the last two decades. In the case of human breast cancer, the combination chemotherapeutic protocol, cyclophosphamide (CPA), doxorubicin (DOX), and 5-fluorouracil (5-FU) (CDF), is often used. Nevertheless, the clinical usefulness of CDF is limited by its remarkably low therapeutic window and frequent eruption of resistance. These limitations prompted our search for a more effective and safe drug candidate that may raise the therapeutic benefits for breast cancer patients. Gingerols’ wide therapeutic indices as well as their high efficacy in the suppression of carcinogenesis are well established. However, no thorough study to date has profiled their antibreast cancer activities in depth. Therefore, the aims of the present study are to evaluate the antibreast cancer activities of gingerols in comparison to CDF and to gain insight into the structure activity relationships (SARs) responsible for the observed effect using a breast cancer cell model, MCF-7. Our data revealed that 6-gingerol showed the highest anticancer potency that is superior to that of CDF with IC50=30.4 μM. Guided by these results, semisynthetic modifications of 6-gingerol have been carried out to characterize 6-gingerol’s SARs. The obtained results showed that the acquisition of free hydroxyl group in the aliphatic side chain of 6-gingerol is essential for the antibreast cancer activity. Likewise, the length of aliphatic side chain in 6-gingerol is optimum for its anticancer activity because any decrease in the side chain length resulted in a dramatic loss of anticancer activity. Additionally, allylation of phenolic group has shown antibreast cancer activity superior to that of 6-gingerol per se. Conversely, methylation or isoprenylation of phenolic group has led to a potential decrease in the anticancer activity, whereas loss of aromaticity resulted in a complete loss of 6-gingerol’s cytotoxic activity. Collectively, the present results would simplify drug design to allow safer and more effective antibreast cancer pharmaceuticals to be designed.",
keywords = "5-fluorouracil, Allyl 6-gingerol, Anticancer drug, Breast cancer, CF-7, Cyclophosphamide, Doxorubicin, Gingerol",
author = "Ibrahim, {Ahmed Salah} and Sobh, {Mohamed A.M.} and Eid, {Hossam Mohammed} and Amgad Salem and Elbelasi, {Hossam Hamza} and El-Naggar, {Mai H.} and Abdelbar, {Fatma M.} and Hussein Sheashaa and Sobh, {Mohamed A.} and Badria, {Farid A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s13277-014-2248-7",
language = "English (US)",
volume = "35",
pages = "9941--9948",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "10",

}

TY - JOUR

T1 - Gingerol-derivatives

T2 - Emerging new therapy against human drug-resistant MCF-7

AU - Ibrahim, Ahmed Salah

AU - Sobh, Mohamed A.M.

AU - Eid, Hossam Mohammed

AU - Salem, Amgad

AU - Elbelasi, Hossam Hamza

AU - El-Naggar, Mai H.

AU - Abdelbar, Fatma M.

AU - Sheashaa, Hussein

AU - Sobh, Mohamed A.

AU - Badria, Farid A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Cancer chemotherapies have been improved dramatically over the last two decades. In the case of human breast cancer, the combination chemotherapeutic protocol, cyclophosphamide (CPA), doxorubicin (DOX), and 5-fluorouracil (5-FU) (CDF), is often used. Nevertheless, the clinical usefulness of CDF is limited by its remarkably low therapeutic window and frequent eruption of resistance. These limitations prompted our search for a more effective and safe drug candidate that may raise the therapeutic benefits for breast cancer patients. Gingerols’ wide therapeutic indices as well as their high efficacy in the suppression of carcinogenesis are well established. However, no thorough study to date has profiled their antibreast cancer activities in depth. Therefore, the aims of the present study are to evaluate the antibreast cancer activities of gingerols in comparison to CDF and to gain insight into the structure activity relationships (SARs) responsible for the observed effect using a breast cancer cell model, MCF-7. Our data revealed that 6-gingerol showed the highest anticancer potency that is superior to that of CDF with IC50=30.4 μM. Guided by these results, semisynthetic modifications of 6-gingerol have been carried out to characterize 6-gingerol’s SARs. The obtained results showed that the acquisition of free hydroxyl group in the aliphatic side chain of 6-gingerol is essential for the antibreast cancer activity. Likewise, the length of aliphatic side chain in 6-gingerol is optimum for its anticancer activity because any decrease in the side chain length resulted in a dramatic loss of anticancer activity. Additionally, allylation of phenolic group has shown antibreast cancer activity superior to that of 6-gingerol per se. Conversely, methylation or isoprenylation of phenolic group has led to a potential decrease in the anticancer activity, whereas loss of aromaticity resulted in a complete loss of 6-gingerol’s cytotoxic activity. Collectively, the present results would simplify drug design to allow safer and more effective antibreast cancer pharmaceuticals to be designed.

AB - Cancer chemotherapies have been improved dramatically over the last two decades. In the case of human breast cancer, the combination chemotherapeutic protocol, cyclophosphamide (CPA), doxorubicin (DOX), and 5-fluorouracil (5-FU) (CDF), is often used. Nevertheless, the clinical usefulness of CDF is limited by its remarkably low therapeutic window and frequent eruption of resistance. These limitations prompted our search for a more effective and safe drug candidate that may raise the therapeutic benefits for breast cancer patients. Gingerols’ wide therapeutic indices as well as their high efficacy in the suppression of carcinogenesis are well established. However, no thorough study to date has profiled their antibreast cancer activities in depth. Therefore, the aims of the present study are to evaluate the antibreast cancer activities of gingerols in comparison to CDF and to gain insight into the structure activity relationships (SARs) responsible for the observed effect using a breast cancer cell model, MCF-7. Our data revealed that 6-gingerol showed the highest anticancer potency that is superior to that of CDF with IC50=30.4 μM. Guided by these results, semisynthetic modifications of 6-gingerol have been carried out to characterize 6-gingerol’s SARs. The obtained results showed that the acquisition of free hydroxyl group in the aliphatic side chain of 6-gingerol is essential for the antibreast cancer activity. Likewise, the length of aliphatic side chain in 6-gingerol is optimum for its anticancer activity because any decrease in the side chain length resulted in a dramatic loss of anticancer activity. Additionally, allylation of phenolic group has shown antibreast cancer activity superior to that of 6-gingerol per se. Conversely, methylation or isoprenylation of phenolic group has led to a potential decrease in the anticancer activity, whereas loss of aromaticity resulted in a complete loss of 6-gingerol’s cytotoxic activity. Collectively, the present results would simplify drug design to allow safer and more effective antibreast cancer pharmaceuticals to be designed.

KW - 5-fluorouracil

KW - Allyl 6-gingerol

KW - Anticancer drug

KW - Breast cancer

KW - CF-7

KW - Cyclophosphamide

KW - Doxorubicin

KW - Gingerol

UR - http://www.scopus.com/inward/record.url?scp=84922394646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922394646&partnerID=8YFLogxK

U2 - 10.1007/s13277-014-2248-7

DO - 10.1007/s13277-014-2248-7

M3 - Article

C2 - 25004806

AN - SCOPUS:84922394646

VL - 35

SP - 9941

EP - 9948

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 10

ER -